The Centre for the Commercialization of Antibodies and Biologics (CCAB) is working with Empirica Therapeutics (Empirica), a Canadian start-up company focused on developing data-driven treatments for cancer, to address the unmet medical needs of glioblastoma (GBM), the most common adult malignant primary brain tumor. Current therapies are only partly effective, with frequent relapse and poor […]
Read More